Table 3.
Reported effects on blood pressure in studies with mineral oil placebo groups
| Author | n a | Dose and mineral oil used | Patient population | Statins | Duration of treatment | SBP | DBP | MAP |
|---|---|---|---|---|---|---|---|---|
| Mortazavi et al.,40 2018 | 23 | 4 g/day, edible paraffin | Male subjects aged 45–55 years with CV disease and ≥50% occlusion in 1 coronary artery | NR | 8 weeks | Decreased 0.29 mmHg | Increased 0.24 mmHg | NR |
| Golzari et al.,41 2019 | 18 | 2 g/day, edible paraffin | Diabetes for ≥1 year, aged 35–50 years, and taking antidiabetic drugs for ≥3 months | NR | 8 weeks |
BL: 124.11 mmHg EOT: 124.89 mmHg |
BL: 80.00 mmHg EOT: 80.00 mmHg |
BL: 94.70 mmHg EOT: 94.96 mmHg |
| Agh et al.,42 2017 | 21 | Edible paraffin |
Men with CAD, ≤50% stenosis in ≥1 major coronary artery in the last 3 months, and BMI ≤30 kg/m2 Individuals using warfarin excluded from participation |
Statin therapy in 92% (does not refer specifically to the control arm) | 8 weeks |
BL: 125.43 mmHg Change: −0.28 mmHg |
BL: 77.86 mmHg Change: +0.23 mmHg |
NR |
| Allain et al.,54 2009 | 8 | 3 g/day, paraffin oil | Healthy volunteers | NR | 6 weeks | NR | NR | Increased from 87.0 to 90.4 mmHg during hyperinsulinemic clamp; P < 0.05 |
| Ferreira et al.,60 2019 | 80 | 5 oral drops of placebo (1% powdered lemon flavour, 0.2% ethylene-diamine-tetraacetic acid, liquid flavour qs, and liquid petrolatum qsp in 20 mL) | Post-menopausal women aged 50–65 years | NR | 9 months |
BL: 136.5 mmHg EOT: 139.0 mmHg P = NS |
BL: 81.0 mmHg EOT: 81.3 mmHg P = NS |
NR |
| Rashidmayvan et al.,61 2019 | 22 | 1 g/day, paraffin oil | Patients aged 20–60 years with non-alcoholic fatty liver disease | NR | 8 weeks |
BL: 125.45 mmHg EOT: 127.77 mmHg P = NS |
BL: 79.45 mmHg EOT: 77.59 mmHg P = NS |
NR |
| Mozaffari-Khosravi et al.,73 2015 | 20 | 1 oral capsule pure liquid paraffin per week | Aged 25–50 years with definite diagnosis of hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) and presence of vitamin D deficiency | NR | 8 weeks |
BL: 145.1 mmHg EOT: 146.0 mmHg |
BL: 93.1 mmHg EOT: 94.1 mmHg |
BL: 110.4 mmHg EOT: 111.4 mmHg |
BL, baseline; BMI, body mass index; CAD, coronary artery disease; CV, cardiovascular; DBP, diastolic blood pressure; EOT, end of treatment; MAP, mean arterial pressure; NR, not reported; OM3, omega-3 fatty acid; SBP, systolic blood pressure.
Number of participants in the mineral oil placebo group.